On January 23, Johnson & Johnson announced its 2023 performance for the full year.Total Revenue 852billion USD, a year-on-year increase of 6.5%. Excluding COVID-19 vaccines, the year-on-year growth was 9%.
Click to download Johnson & Johnson's 2023 earnings report PPT
After officially completing the spin-off of its consumer health business in 2023, Johnson & Johnson is for the first time focusing onMedical Technology and Pharmaceutical IndustriesA major pharmaceutical company disclosed its annual performance. The financial report shows,Johnson & Johnson 2023Pharmaceuticals business achieved revenue of $54.759 billion (+4.2%), while medical technology business revenue reached $30.4 billion (+10.8%).
Click to download Johnson & Johnson's 2023 earnings PPT
Johnson & Johnson's pharmaceutical business mainly focuses on several major fields: immunology, oncology, neuroscience, infectious diseases, pulmonary arterial hypertension, cardiovascular and metabolic diseases. Among them, the immunology and oncology businessesEqually matched,Contributed 180.52 (+6.6%) and 176.61 (+10.5%), respectively.Billion USD in revenue,Is driving the performance growth of Johnson & JohnsonThe CorePillar。
Johnson & Johnson 2023Main Product Sales (USD billion)The growth of Johnson & Johnson's oncology business is mainly attributed to Darzalex (Daratumumab),Erleada（Apalutamide）、ImbruVica (IbuprofenTinib）, Zytiga (Abiraterone),CarvyKTI (Cilta-cel)Driven by strong products.Among them, the main member DaRzalex, thanks to the full-line treatment of multiple myeloma (MM), its market share continues to expand.2023MaintainHigh growth trend (+22.2%）Contributed 97.44Billion-dollar revenue, nearly achieving 10 billion in sales。Multiple myeloma is one of the key areas of focus for Johnson & Johnson's oncology efforts. At this stage,Johnson & Johnson has already planned in this fieldMonoclonal antibodies, bispecific antibodies, cell therapy, and induced pluripotent stem cell combination strategies aim to redefine MM.Treatment model. Specific products includeIn collaboration with LegendBCMA CAR-T Cell TherapyCarvy MethodKTI, BCMAxCD3 bispecific antibody Teclistamab, and GPRC5DxCD3 bispecific antibody Talquetamab have been successively launched in the past two years, continuously expanding Johnson & Johnson's portfolio in China.Competitive advantages in the field of hematological tumors.Among them,CarvyktiUpThe city reached 500 million US dollars in revenue in the second year.In 2023,CarvyKTI has also made significant progress, itsFor adult MM patients who have previously received one to three lines of therapy and are lenalidomide-resistantThe Phase III Clinical CARTUDE-4 Study AchievedStunning efficacy results, capable ofReduced Risk of Disease Progression or Death74%. Based on the study results, CarvyktiSecond to Fourth-Line TreatmentMM PatientsTheThe listing application has been accepted by the FDA.Li,PDUFA DayPeriodApril 5, 2024.It can be foreseen that, with the gradual shift of indications,CarvyKTI sales will achieve further breakthroughs.Broken。Johnson & Johnson also has significant advantages in the field of prostate cancer, now relying onZytiga、Erleada's two products have taken the leading position in the prostate cancer market.Zytiga was first launched in the U.S. in 2011 and can be used to treatPatients with castration-resistant prostate cancer and hormone-sensitive prostate cancer. In 2018, the U.S. patent for this product expired, and since then, sales have seen...Cliff-likeDecline,In 2023, it plummeted to USD 8.87 billion (-49.9%).。To this end, Johnson & Johnson, on the one handAroundZYtiga explores the potential of combination use with NiraparibCombination (Akeega）It has been approved for marketing by the EU and FDA in 2023 successively; on the other hand, Johnson & Johnson also launched a follow-up product in 2018.ProductErleada, Since its launch, the drug has maintained a double-digit growth trend, with revenue reaching $2.387 billion in 2023 (26.9%), successfullyPromotion to Johnson & Johnson Prostate CancerA Rising Star in the Field.In the field of autoimmune,Stelara (Ustekinumab)Nudanab),Remicade（Infliximab）、Tremfya（Guselkumab）、Simponi（Golimumab) and other products jointly drove Johnson & Johnson's revenue growth, contributing a total of $18.041 billion in revenue. However,Remicade is affected byImpact of Biosimilar Competition,Sales have been falling year by year.In 2023, it only reached 1.839 billion US dollars.StelaraRemains the main growth driver of Johnson & Johnson's immunology segment and the best-selling product in Johnson & Johnson's pharmaceutical business, with an 11.7% year-over-year increase to $10.858 billion in 2023.Officially Enter the Billion-Dollar MarketClub, but its U.S. patent expired in September 2023, meaning that in the coming yearsWill face a crowd of biosimilar drugs.Currently, GlobalThere are already twoUstekinumab BiosimilarApproved for Marketing, 2 applications for marketing approval,Analysts predict that by 2024StelaraSales may shrink by $20 billion.The international competition in the autoimmune field has always been fierce, and with the叠加 patent cliff, Johnson & Johnson's product layout in the autoimmune field is likely to face challenges.Facing the dilemma of "internal and external troubles." To this end, Johnson & Johnson isLooking for the next engine to support the continued growth of self-immune performance, in addition to further exploring the therapeutic potential of mature products, Johnson & Johnson is alsoCultivate new products through self-research and introduction.Among them, Johnson & Johnson in 2020Nipocalimab, an FcRn monoclonal antibody introduced from Momenta for $6.5 billion, is highly anticipated and is currentlySynchronously carry out forWarm Antibody TypeAutoimmuneEpidemicHemolytic AnemiaBlood (Phase III), Giant Cell Arteritis (Phase II),Idiopathic Inflammatory Myopathy (Phase II), Hemolytic Disease of the Fetus and Newborn (Phase II), Sjögren's Syndrome (Phase II), Systemic Lupus Erythematosus (Phase II), etc.Multiple Clinical Studies。In addition, the three candidate small-molecule IL-23R inhibitors that Johnson & Johnson introduced from Protagonist in 2019Also enters Phase I~IIIClinical Development Stage;Among them, JNJ-2113 is the most advanced, currently under investigation for the treatment of plaque psoriasis.Phase III Study.In order to further focus on innovative drug research and development, Johnson & Johnson completed an inside-out transformation in 2023.Including the completion of its stock-for-stock offer with consumer health company Kenvue in August 2023, at the same timeRetained the two major businesses of medical technology and pharmaceuticals, and willPharmaceutical Business "Janssen" Renamed to"Johnson & Johnson Innovative Pharmaceuticals",A brand with over 135 years of historyThe logo has also been refreshed. This business adjustment and brand重塑,Not only did it convey Johnson & Johnson's new image to the outside world, but it also reflected to a certain extentJohnson & Johnson Bids Farewell to the Past, Leading the Future of Healthcare Industry DevelopmentThe Ambition.In 2023, Johnson & Johnson's pharmaceutical business also made significant progress in regulatory approvals for new drugs/indications, submissions of marketing applications, and the readout of clinical data (as shown in the figure below).For the 2024 performance outlook, Johnson & Johnson expects a 5%-6% increase, with total revenue expected to reach $88.2-$89 billion.Copyright © 2024 PHARMCUBE. All Rights Reserved.Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message to the WeChat Official Account backend or send a message, and indicate the name and ID of the official account.Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
